BI debuts two PRRS vaccines; Merck launches graduate fellowships; Jaguar starts trials for Neonorm Foal;

> Boehringer Ingelheim Animal Health announced that it has launched two vaccines in Europe to protect against Porcine Reproductive and Respiratory Syndrome (PRRS). Release

> Merck ($MRK) Animal Health has partnered with the Poultry Science Association Foundation to establish fellowships for graduate students interested in poultry intestinal health, immunology, disease, molecular biology or vaccine development. More

> Jaguar Animal Health ($JAGX) announced that it has launched a proof-of-concept study of Neonorm Foal Plus, an equine version of its product Neonorm Calf. Release

> Patterson Companies ($PDCO) declared a quarterly cash dividend of $0.22 a share, payable October 30. Release

> Bayer Animal Health has launched Claro Otic Solution, the first single-dose drug to treat canine otitis externa, a common and painful ear infection in dogs. Release

> NatPets of Boulder, CO, expanded its recall of cow-boom! strips-beef gullet because of possible contamination with Salmonella. Release

> IDEXX Laboratories ($IDXX) has partnered with the Ontario Veterinary Medical Association to create a dashboard that will help veterinary practices track benchmarks and metrics. Release

> Cook Animal Health of Bloomington, IN, announced a partnership with MILA International, which will distribute more than 100 Cook devices to veterinary practices. Release

> The state of Texas has confirmed 19 cases of West Nile virus in horses, the majority of which had not been vaccinated against the disease. Article

> Zoetis ($ZTS) was named a top 10 company for working mothers by Working Mother magazine for the second year in a row. Release

> Switzerland-based Gour Medical has signed an exclusive agreement to manufacture and market SolMic Research's cannabidiol products for use in animal health. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…